Drugs / IBI3028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07589205 | Mar 2026 → Jun 2027 expected | colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589205 ↗ |
| Target | EGFR | “Recombinant anti-EGFR（Epidermal growth factor receptor） and c-Met antibodies-dual-payload conjugate for injection” NCT07589205 ↗ |
| Target | MET | “Recombinant anti-EGFR（Epidermal growth factor receptor） and c-Met antibodies-dual-payload conjugate for injection” NCT07589205 ↗ |